Prospects for new TB vaccines: Stop TB Working Group on TB Vaccine Development

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 1, 2004, Pages 151-155

  Fruth, Uli ^a   Young, D ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Development; Laboratory; Tuberculosis; Vaccines

Indexed keywords

BCG VACCINE; DNA VACCINE;

BCG VACCINATION; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SCREENING; FINANCIAL MANAGEMENT; HEALTH CARE FACILITY; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; IMMUNOPROPHYLAXIS; LABORATORY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANIMALS; CLINICAL TRIALS, PHASE I; COMMUNICABLE DISEASE CONTROL; DRUG INDUSTRY; FEMALE; GREAT BRITAIN; GUINEA PIGS; HUMANS; IMMUNIZATION PROGRAMS; MALE; MICE; ORGANIZATIONS, NONPROFIT; RESEARCH SUPPORT; SENSITIVITY AND SPECIFICITY; TECHNOLOGY, PHARMACEUTICAL; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 1642475493     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Black G F, Weir R E, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359: 1393-1401.
2. Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70: 672-678.
3. Cole S T, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-544.
4. Glickman M S, Jacobs W R Jr. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell 2001; 104: 477-485.
5. Kaufmann S H E. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol 2001; 1: 20-30.
6. Behr M A, Wilson M A, Gill W P, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999; 284: 1520-1523.
7. Pym A S, Brodin P, Brosch R, Huerre M, Cole S T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 2002; 46: 709-717.
8. Horwitz M A, Harth G, Dillon B J, Maslesa-Galic S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000; 97: 13853-13858.
9. Hess J, Miko D, Catic A, Lehmensiek V, Russell D G, Kaufmann S H. Mycobacterium bovis Bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 1998; 95: 5299-5304.
10. Camacho L R, Ensergueix D, Perez E, Gicquel B, Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 1999; 34: 257-267.
11. Cox J S, Chen B, McNeil M, Jacobs W R Jr. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 1999; 402: 79-83.
12. Smith D A, Parish T, Stoker N G, Bancroft G J. Characterization of anxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates. Infect Immun. 2001; 69: 1142-1150.
13. Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001; 41: 179-187.
14. McKinney J D, Honer zu Bentrup K, Munoz-Elias E J, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-738.
15. Stewart G R, Snewin V A, Walzl G, et al. Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nat Med 2001; 7: 732-737.
16. Baldwin S L, D'Souza C, Roberts A D, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 1998; 66: 2951-2959.
17. Weinrich Olsen A, van Pinxteren L A, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infect Immun 2001; 69: 2773-2778.
18. Coler R N, Campos-Neto A, Ovendale P, et al. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol 2001; 166: 6227-6235.
19. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2: 893-898.
20. Lowrie D B, Tascon R E, Bonato V L, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269-271.
21. McShane H, Brookes R, Gilbert S C, Hill A V. Enhanced immunogenicity of CD4(-) T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect Immun 2001; 69: 681-686.
22. Orme I M, McMurray D N, Belisle J T. Tuberculosis vaccine development: recent progress. Trends Microbiol 2001; 9: 115-118.
23. Langermans J A, Andersen P, van Soolingen D, et al. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proc Natl Acad Sci USA 2001; 98: 11497-11502.
24. European Commission. TB Vaccine Cluster. The cluster for tuberculosis vaccine development. Accessed 27.10.03. http://www.pasteur.fr/recherche/EC_TBvaccine/
25. Brennan MJ, Fruth U. Conference Report: Global Forum on TB Vaccine Research and Development. Geneva: World Health Organization, June 7-8, 2001. Tuberculosis 2001; 81: 365-368.
26. Reed S G, Alderson M R, Dalemans W, Lobet Y, Skeiky Y A W. Prospects for a better vaccine against tuberculosis. Tuberculosis 2003; 83: 213-219.
27. von Reyn C F, Vuola J M. New vaccines for the prevention of tuberculosis. Clin Infect Dis 2002; 35: 465-474.
28. Durban Immunotherapy Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Lancet 1999; 354: 116-119.